← ANALYST RATINGS · TIPRANKS
Telix Pharmaceuticals Limited Unsponsored ADR (TLX): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $20.00, the highest $20.00, the lowest $20.00. The average is +87.1% from the last price of $10.69.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $20.00 | Buy | +87.1% | Reiterated | 30.09.26on TipRanks 06:25 | −3.1%next day −2.5% · 5 days −0.5% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $13.00 | Hold | +21.6% | Initiated | 23.09.26on TipRanks 11:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.50 | Hold | +16.9% | Initiated | 23.09.26on TipRanks 11:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.50 | Hold | +16.9% | Initiated | 23.09.26on TipRanks 11:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.50 | Hold | +16.9% | Initiated | 23.09.26on TipRanks 11:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $13.00 | Buy | +21.6% | Initiated | 23.09.26on TipRanks 11:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.50 | Hold | +16.9% | Initiated | 23.09.26on TipRanks 11:05 | — | |
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Buy | — | Reiterated | 22.09.26on TipRanks 15:07 | +5.7%next day −5.0% · 5 days −3.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Telix Pharmaceuticals Limited Unsponsored ADR
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $20.00 at a price of $10.97 (+82.3%); now: $20.00 at $10.69 (+87.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 19.02.27 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.07 (from $-0.10 to $-0.04). Last quarter: $0.17.
Sales
Next quarter’s sales estimate — $495M (from $488M to $503M). Last quarter: $479M.
Best top-analyst consensus in the sector · General
About Telix Pharmaceuticals Limited Unsponsored ADR
- CEO: Christian Behrenbruch
- Employees: 1,152
- 55 Flemington Road, North Melbourne, VIC, 3051, AU
- telixpharma.com
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Data from the stock’s TipRanks forecast page, read 180 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗